Format

Send to

Choose Destination
Curr Opin Investig Drugs. 2005 Apr;6(4):419-26.

MK-431 (Merck).

Author information

1
Department of Medical Physiology, Panum Institute, University of Copenhagen, DK-2200 Copenhagen N, Denmark. deacon@mfi.ku.dk

Abstract

Merck & Co is developing MK-431, the lead from a series of dipeptidyl peptidase IV inhibitors that enhance endogenous glucagon-like peptide-1 levels, for the potential treatment of type 2 diabetes. Phase III studies were initiated in the second quarter of 2004.

PMID:
15898349
[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center